Biotechnology company, Amgen, has announced that it has entered ... (July 8-10, 2025). The ISPE Singapore Affiliate Conference & Exhibition is one of the largest and most respected events for ...

Originally approved by the FDA in 1998, Amgen’s Enbrel is still sailing along without facing biosimilar competition in the ...

Amgen has reported encouraging mid-stage results ... Final results of the OCEAN(a)-DOSE trial – published in the New England Journal of Medicine – showed that the small, interfering RNA ...

Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the U.S. against Amgen for ...

Sandoz files U.S. antitrust lawsuit against Amgen over arthritis drug Swiss generic ... of the market position of its blockbuster medicine, Enbrel (etanercept). Global drugmakers' stocks dropped ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesCompany aims to accelerate access to much-needed biosimilar to reference ...